Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial

Carl E. Allen, Theodore W. Laetsch, Rajen Mody, Meredith S. Irwin, Megan S. Lim, Peter C. Adamson, Nita L. Seibel, D. Williams Parsons, Y. Jae Cho, Katherine Janeway, James Amatruda, Alice Chen, Amar Gajjar, Jim Geller, Richard Gorlick, Terzah Horton, Javed Khan, Stephen Lessnick, Mei Polley, Greg ReamanGiles Robinson, Malcolm Smith, Naoko Takebe, Pediatric MATCH Target and Agent Prioritization Committee

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Over the past decades, outcomes for children with cancer have improved dramatically through serial clinical trials based in large measure on dose intensification of cytotoxic chemotherapy for children with high-risk malignancies. Progress made through such dose intensification, in general, is no longer yielding further improvements in outcome. With the revolution in sequencing technologies and rapid development of drugs that block specific proteins and pathways, there is now an opportunity to improve outcomes for pediatric cancer patients through mutation-based targeted therapeutic strategies. The Children's Oncology Group (COG), in partnership with the National Cancer Institute (NCI), is planning a trial entitled the COG-NCI Pediatric Molecular Analysis for Therapeutic Choice (Pediatric MATCH) protocol utilizing an umbrella design. This protocol will have centralized infrastructure and will consist of a biomarker profiling protocol and multiple single-arm phase II trials of targeted therapies. Pediatric patients with recurrent or refractory solid tumors, lymphomas, or histiocytoses with measurable disease will be eligible. The Pediatric MATCH Target and Agent Prioritization (TAP) committee includes membership representing COG disease committees, the Food and Drug Administration, and the NCI. The TAP Committee systematically reviewed target and agent pairs for inclusion in the Pediatric MATCH trial. Fifteen drug-target pairs were reviewed by the TAP Committee, with seven recommended for further development as initial arms of the Pediatric MATCH trial. The current evidence for availability, efficacy, and safety of targeted agents in children for each class of mutation considered for inclusion in the Pediatric MATCH trial is discussed in this review.

Original languageEnglish (US)
Article numberdjw274
JournalJournal of the National Cancer Institute
Volume109
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

National Cancer Institute (U.S.)
Pediatrics
Therapeutics
Neoplasms
Histiocytosis
Committee Membership
Mutation
United States Food and Drug Administration
Pharmaceutical Preparations
Lymphoma
Biomarkers
Clinical Trials
Technology
Safety
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Allen, C. E., Laetsch, T. W., Mody, R., Irwin, M. S., Lim, M. S., Adamson, P. C., ... Pediatric MATCH Target and Agent Prioritization Committee (2017). Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial. Journal of the National Cancer Institute, 109(5), [djw274]. https://doi.org/10.1093/jnci/djw274

Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial. / Allen, Carl E.; Laetsch, Theodore W.; Mody, Rajen; Irwin, Meredith S.; Lim, Megan S.; Adamson, Peter C.; Seibel, Nita L.; Parsons, D. Williams; Cho, Y. Jae; Janeway, Katherine; Amatruda, James; Chen, Alice; Gajjar, Amar; Geller, Jim; Gorlick, Richard; Horton, Terzah; Khan, Javed; Lessnick, Stephen; Polley, Mei; Reaman, Greg; Robinson, Giles; Smith, Malcolm; Takebe, Naoko; Pediatric MATCH Target and Agent Prioritization Committee.

In: Journal of the National Cancer Institute, Vol. 109, No. 5, djw274, 01.05.2017.

Research output: Contribution to journalReview article

Allen, CE, Laetsch, TW, Mody, R, Irwin, MS, Lim, MS, Adamson, PC, Seibel, NL, Parsons, DW, Cho, YJ, Janeway, K, Amatruda, J, Chen, A, Gajjar, A, Geller, J, Gorlick, R, Horton, T, Khan, J, Lessnick, S, Polley, M, Reaman, G, Robinson, G, Smith, M, Takebe, N & Pediatric MATCH Target and Agent Prioritization Committee 2017, 'Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial', Journal of the National Cancer Institute, vol. 109, no. 5, djw274. https://doi.org/10.1093/jnci/djw274
Allen, Carl E. ; Laetsch, Theodore W. ; Mody, Rajen ; Irwin, Meredith S. ; Lim, Megan S. ; Adamson, Peter C. ; Seibel, Nita L. ; Parsons, D. Williams ; Cho, Y. Jae ; Janeway, Katherine ; Amatruda, James ; Chen, Alice ; Gajjar, Amar ; Geller, Jim ; Gorlick, Richard ; Horton, Terzah ; Khan, Javed ; Lessnick, Stephen ; Polley, Mei ; Reaman, Greg ; Robinson, Giles ; Smith, Malcolm ; Takebe, Naoko ; Pediatric MATCH Target and Agent Prioritization Committee. / Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial. In: Journal of the National Cancer Institute. 2017 ; Vol. 109, No. 5.
@article{70fb05f3d2364351930c1d29db78ef28,
title = "Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial",
abstract = "Over the past decades, outcomes for children with cancer have improved dramatically through serial clinical trials based in large measure on dose intensification of cytotoxic chemotherapy for children with high-risk malignancies. Progress made through such dose intensification, in general, is no longer yielding further improvements in outcome. With the revolution in sequencing technologies and rapid development of drugs that block specific proteins and pathways, there is now an opportunity to improve outcomes for pediatric cancer patients through mutation-based targeted therapeutic strategies. The Children's Oncology Group (COG), in partnership with the National Cancer Institute (NCI), is planning a trial entitled the COG-NCI Pediatric Molecular Analysis for Therapeutic Choice (Pediatric MATCH) protocol utilizing an umbrella design. This protocol will have centralized infrastructure and will consist of a biomarker profiling protocol and multiple single-arm phase II trials of targeted therapies. Pediatric patients with recurrent or refractory solid tumors, lymphomas, or histiocytoses with measurable disease will be eligible. The Pediatric MATCH Target and Agent Prioritization (TAP) committee includes membership representing COG disease committees, the Food and Drug Administration, and the NCI. The TAP Committee systematically reviewed target and agent pairs for inclusion in the Pediatric MATCH trial. Fifteen drug-target pairs were reviewed by the TAP Committee, with seven recommended for further development as initial arms of the Pediatric MATCH trial. The current evidence for availability, efficacy, and safety of targeted agents in children for each class of mutation considered for inclusion in the Pediatric MATCH trial is discussed in this review.",
author = "Allen, {Carl E.} and Laetsch, {Theodore W.} and Rajen Mody and Irwin, {Meredith S.} and Lim, {Megan S.} and Adamson, {Peter C.} and Seibel, {Nita L.} and Parsons, {D. Williams} and Cho, {Y. Jae} and Katherine Janeway and James Amatruda and Alice Chen and Amar Gajjar and Jim Geller and Richard Gorlick and Terzah Horton and Javed Khan and Stephen Lessnick and Mei Polley and Greg Reaman and Giles Robinson and Malcolm Smith and Naoko Takebe and {Pediatric MATCH Target and Agent Prioritization Committee}",
year = "2017",
month = "5",
day = "1",
doi = "10.1093/jnci/djw274",
language = "English (US)",
volume = "109",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Target and Agent Prioritization for the Children's Oncology Group - National Cancer Institute Pediatric MATCH Trial

AU - Allen, Carl E.

AU - Laetsch, Theodore W.

AU - Mody, Rajen

AU - Irwin, Meredith S.

AU - Lim, Megan S.

AU - Adamson, Peter C.

AU - Seibel, Nita L.

AU - Parsons, D. Williams

AU - Cho, Y. Jae

AU - Janeway, Katherine

AU - Amatruda, James

AU - Chen, Alice

AU - Gajjar, Amar

AU - Geller, Jim

AU - Gorlick, Richard

AU - Horton, Terzah

AU - Khan, Javed

AU - Lessnick, Stephen

AU - Polley, Mei

AU - Reaman, Greg

AU - Robinson, Giles

AU - Smith, Malcolm

AU - Takebe, Naoko

AU - Pediatric MATCH Target and Agent Prioritization Committee

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Over the past decades, outcomes for children with cancer have improved dramatically through serial clinical trials based in large measure on dose intensification of cytotoxic chemotherapy for children with high-risk malignancies. Progress made through such dose intensification, in general, is no longer yielding further improvements in outcome. With the revolution in sequencing technologies and rapid development of drugs that block specific proteins and pathways, there is now an opportunity to improve outcomes for pediatric cancer patients through mutation-based targeted therapeutic strategies. The Children's Oncology Group (COG), in partnership with the National Cancer Institute (NCI), is planning a trial entitled the COG-NCI Pediatric Molecular Analysis for Therapeutic Choice (Pediatric MATCH) protocol utilizing an umbrella design. This protocol will have centralized infrastructure and will consist of a biomarker profiling protocol and multiple single-arm phase II trials of targeted therapies. Pediatric patients with recurrent or refractory solid tumors, lymphomas, or histiocytoses with measurable disease will be eligible. The Pediatric MATCH Target and Agent Prioritization (TAP) committee includes membership representing COG disease committees, the Food and Drug Administration, and the NCI. The TAP Committee systematically reviewed target and agent pairs for inclusion in the Pediatric MATCH trial. Fifteen drug-target pairs were reviewed by the TAP Committee, with seven recommended for further development as initial arms of the Pediatric MATCH trial. The current evidence for availability, efficacy, and safety of targeted agents in children for each class of mutation considered for inclusion in the Pediatric MATCH trial is discussed in this review.

AB - Over the past decades, outcomes for children with cancer have improved dramatically through serial clinical trials based in large measure on dose intensification of cytotoxic chemotherapy for children with high-risk malignancies. Progress made through such dose intensification, in general, is no longer yielding further improvements in outcome. With the revolution in sequencing technologies and rapid development of drugs that block specific proteins and pathways, there is now an opportunity to improve outcomes for pediatric cancer patients through mutation-based targeted therapeutic strategies. The Children's Oncology Group (COG), in partnership with the National Cancer Institute (NCI), is planning a trial entitled the COG-NCI Pediatric Molecular Analysis for Therapeutic Choice (Pediatric MATCH) protocol utilizing an umbrella design. This protocol will have centralized infrastructure and will consist of a biomarker profiling protocol and multiple single-arm phase II trials of targeted therapies. Pediatric patients with recurrent or refractory solid tumors, lymphomas, or histiocytoses with measurable disease will be eligible. The Pediatric MATCH Target and Agent Prioritization (TAP) committee includes membership representing COG disease committees, the Food and Drug Administration, and the NCI. The TAP Committee systematically reviewed target and agent pairs for inclusion in the Pediatric MATCH trial. Fifteen drug-target pairs were reviewed by the TAP Committee, with seven recommended for further development as initial arms of the Pediatric MATCH trial. The current evidence for availability, efficacy, and safety of targeted agents in children for each class of mutation considered for inclusion in the Pediatric MATCH trial is discussed in this review.

UR - http://www.scopus.com/inward/record.url?scp=85021347338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021347338&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw274

DO - 10.1093/jnci/djw274

M3 - Review article

AN - SCOPUS:85021347338

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

M1 - djw274

ER -